Navigating Access to Cancer Care: Identifying Barriers to Precision Cancer Medicine
Ethnicity & Disease · 20.01.2022 · 32 (1) · 39-48
DOI: 10.18865/ed.32.1.39 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ethnicity & Disease, online erschienen am 20.01.2022. Verfasst von Kayla E Cooper und 4 weiteren Autor:innen. Beteiligte Einrichtung: Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD. Hauptthemen laut MEDLINE: Neoplasms, Precision Medicine. Die Arbeit wurde bisher 21-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
Precision medicine is revolutionizing cancer treatment. However, there has been limited investigation of barriers patients endure to access precision cancer medicine. This study aims to report the experiences of underserved patient populations with limited access to genomic testing, clinical trials, and precision cancer treatment.
Methods
A mixed-method study was employed to quantitatively evaluate patients (N=300) seeking precision cancer medicine between January 2014- August 2017. Qualitatively, we conducted semi-structured interviews with eight case managers who navigate the health care and health insurance systems to provide patients with access to precision cancer medicine care. All interviews were analyzed to identify themes.
Results
Within our patient cohort, 69% were diagnosed in stage I of cancer disease. Overall, 27 patients (9%) were denied treatment as a final outcome of their case due to insurance denials, 35 patients (12%) died before gaining access to precision cancer medicine, and 6 patients (2%) received precision cancer medicine through clinical trials. Four broad thematic areas emerged from the qualitative analysis: 1) lack of patient, provider and insurer knowledge of precision cancer medicine; 2) barriers to clinical trial participation; 3) lack of patient health literacy; and 4) barriers to timely access to care.
Conclusion
Our combined analyses suggest that both system-level and patient-level barriers limit patient access to precision cancer medicine options. Additionally, we found that these barriers may exist not only for traditionally underserved patients, but also for resourced and insured patients trying to access precision cancer medicine. Ethn Dis. 2022;32(1):39-48; doi:10.18865/ed.32.1.39
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.
- Department of Research and Evaluation, Patient Advocate Foundation, Hampton, VA.
Förderung
- Intramural NIH HHS
Zitieren
APA
Cooper, K. E., Abdallah, K. E., Angove, R. S. M., Gallagher, K. D., & Bonham, V. L. (2022). Navigating Access to Cancer Care: Identifying Barriers to Precision Cancer Medicine. Ethnicity & Disease, 32(1), 39-48. https://doi.org/10.18865/ed.32.1.39
Vancouver
Cooper KE, Abdallah KE, Angove RSM, Gallagher KD, Bonham VL. Navigating Access to Cancer Care: Identifying Barriers to Precision Cancer Medicine. Ethnicity & Disease. 2022;32(1):39-48. doi:10.18865/ed.32.1.39
BibTeX
@article{Cooper2022,
author = {Cooper, Kayla E and Abdallah, Khadijah E and Angove, Rebekah S M and Gallagher, Kathleen D and Bonham, Vence L},
title = {Navigating Access to Cancer Care: Identifying Barriers to Precision Cancer Medicine},
journal = {Ethnicity & Disease},
year = {2022},
volume = {32},
number = {1},
pages = {39--48},
doi = {10.18865/ed.32.1.39}
}
EUVIMED